Group items matching

in title, tags, annotations or url

What can be done? What can't be done? What needs to be done? When can it be done? What is realistic?

new ideas were further refined

systematic analysis and planning

Working Groups of NIH staff, along with ad hoc outside advisors, were formed

Each working group presented their top initiatives

Is the initiative truly transforming—will it dramatically change how or what biomedical research is conducted in the next decade? Would the outcomes from the initiative be used by and synergize the work of many NIH Institutes and Centers? Can the NIH afford NOT to do it? Will the initiative be compelling to our stakeholders, especially the public?

The Roadmap working groups were grouped into nine Implementation Groups

implementation plans

timelines, milestones, mechanisms for coordination, need for inventories, and staffing needed for program implementation

AGS Foundation for Health in Aging

American Geriatrics Society

American Society on Aging

The Centenarian

ConsultGeriRN

Foundation Aiding the Elderly (F.A.T.E.)

Gerontological Society of America (GSA)

Huffington Center on Aging/ Baylor College of Medicine

International Association of Gerontology

International Council on Active Aging

International Longevity Center (ILC)

Leadership Council of Aging Organizations

Health & Aging Agencies/Institutes Buck Institute Cancer Research Institute Institute for Advanced Studies in Aging & Geriatric Medicine National Council on the Aging National Heart, Lung and Blood Institute National Institute of Arthritis and Musculoskeletal and Skin Disease (NIAMS) National Institute of Diabetes & Digestive and Kidney Diseases National Institute of Health (NIH) National Institute of Mental Health (NIMH) National Institute on Aging Senate Special Committee on Aging Senior Citizens' Resources United States EPA Aging Initiative U.S. Administration on Aging Women's Research & Education Institute

National Council on Aging

May 2008 - CIRM, the California Institute for Regenerative Medicine awards the Buck $20.5 million in seed money to build a new facility for stem cell research. The new facility would be the 2nd research building to be constructed on the campus.

Я пытаюсь действовать в трех главных направлениях:  - я занимаюсь исследованиями в области биогеронтологии  - я обеспечиваю использование технических подходов для борьбы с различными аспектами старения  - я участвую в различных дискуссиях на эти темы...

лаборатория занимается выявлением механизмов возникновения возраст-ассоциированных мутаций и их проявлению в фенотипе стареющего организма.

Ян Видж- генетик из Buck Institute for Age Research. Он является автором знаменитой книги "Aging of the Genome" (Старение генома). Видж изучает явление нестабильности генома, роль которого в старении активно обсуждается с 1940-х годов, когда было открыто, что ежедневные малые дозы радиации вызывают ускоренное страение у грызунов

При участии Виджа была создана MPHASYS-система для анализа мышиного фенотипа. Т.к. большинство исследований проводится на мышах, то существовала определенная проблема с систематизацией данных. Благодаря созданию MPHASYS (Mouse Phenotype Analysis System) произошла интеграция различных исследований, моделирующих заболевания и процесс старения человека на мыши. Этот великолепный пример системного подхода несомненно сыграет большую роль в раскрытии механизмов старения.

Область научных интересов Эймса связана со старением и раком. Он является признаным экспертом в этой области. Сейчас Эймс заинтересовался проблемами, связанными с митохондриями: их старение, повреждение мтДНК и пр. Также он занимается проблемой мутагенов, предотвращением онкологических заболеваний и старения.

Эймс занимается сразу и генетикой, и биохимией, и молекулярной биологией, и онкологией, и нутрициологией,и даже нутригеномикой, а главное- все это он использует на благо геронтологии в целях борьбы со старением.

Его метод-сравнительная биогеронтология, использование клеток, выделенных из различных коротко- и долгоживущих видов животных, в том числе летучих мышей, белок, мартышек, бабуинов и лабораторных мышей. Остад сравнивает эти клетки по сопротивляемости стрессу, изучает механизмы этой сопротивляемости, в том числе и сопротивляемость и репарация повреждений ДНК. Он выяснил, что долголетие видов напрямую связано с уровнем клеточной сопротивляемости стрессу.

Аркинг занимается изучением старения на мухе Drosophila-классическом объекте исследований биологов разных направлений. Он создает контрольный тип этих мух, а затем с помощью искусственного отбора создает из него несколько долгоживущих типов

I think this is quite a new concept because not until recently have we begun to understand a little bit more about the aging process and find some biochemical pathways that are at the root of aging processes.

Now what do you see as the greatest challenges for developing drugs that deal with aging? Would you say that it’s more regulatory and policy wise, or is this more scientific?

I think there is both.

When I was heading aging at Glaxo Smith Kline, the issues that I faced were that I was very interested in developing medications for frailty and weakness in muscle for when people get old because when people get weak they usually stop eating and then they fall and break a hip and end up in the hospital and die potentially, but the regulatory apparatus isn’t there yet.

Sarcopenia isn’t recognized as an official disease by the FDA, so the pathway to get drugs approved for frailty and to get more people mobile and into society is just not there, and so it’s a really difficult problem, and the pathways for osteoporosis are still very cumbersome, requiring fracture analysis.

There isn’t an approved, for example, like Jack Coralnick uses a scale at NIH to test people’s function. I think there is a critical need to have the FDA to recognize some battery of functional tests

how a reform would take place

Well we have a new FDA now, hopefully, but it’s going to take companies and scientists going to the FDA and to Congress to say “look the patient population is aging and currently we have a bottleneck, we can’t get these medicines through” and try to work out some new policy. Hopefully, the FDA will be a little more progressive about looking at endpoints. They are very, very conservative about what endpoints they will accept

You know, there is understandably some concern that people might use these drugs and abuse them for muscle building, but on the other hand, there is a critical unmet need out there in the elderly population

Well one thing is that it is quite difficult and expensive to develop drugs for aging per se because even to do pre-clinical models in animals is very expensive. It’s very expensive to get aged animals, and they don’t necessarily act like aged humans. So even in the pre-clinical stage, it’s a difficult area to work in.

find pathways to get these drugs approved

a lot of these companies are concerned as being seen as trying to produce “fountain of youth” drugs. I made it very clear when I was leading aging at GSK that I was not attempting simply to extend lifespan

I think this is a policy challenge and a perceptual challenge and if you will, a public relations challenge.

Potentially, I think we need to find more intelligent, creative ways to do clinical trials using biomarkers or other types of measures where we can get the trials through quickly

again, it goes back to the FDA policy. The FDA is going to have to be willing to accept some of these things, or we will not be able to get these drugs on the market